LBA10 Primary Endpoint Results of the Neo-CheckRay Phase II Trial Evaluating Stereotactic Body Radiation Therapy (SBRT) +/- Durvalumab (durva) +/- Oleclumab (ole) Combined with Neo-Adjuvant Chemotherapy (NACT) for Early-Stage, High Risk ER+/HER2- Breast Cancer (BC)
Annals of Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined